CA
NZ
UK
AU
IND
US
Chronic low back pain is one of medicine's most expensive and frustrating puzzles, and Aclarion (NASDAQ:ACON) is betting that artificial intelligence can help solve it. The Broomfield, Colorado company's flagship product, Nociscan, uses magnetic resonance spectroscopy and proprietary algorithms to pinpoint which spinal discs …
Aptevo Therapeutics (NASDAQ:APVO) is a clinical-stage cancer-immunotherapy company betting almost everything on one molecule: mipletamig, a bispecific antibody being tested in newly diagnosed acute myeloid leukemia. In 2026 the company has reported eye-catching early efficacy data that appears to outperform a widely cited historical …
Altimmune Inc. reported positive trial results, which sent shares surging. The biotech sector is known for its volatility, and companies like Altimmune must demonstrate their ability to deliver innovative treatments. Positive trial results can be a critical catalyst for biotech stocks, as they often …
BioNexus Gene Lab Corp (NASDAQ: BGLC) announced that its VitaGuard molecular residual disease assay will soon be deployed throughout Southeast Asia, with the per‑test price intended to remain under US $300. The company points to the sizable population covered by its licensed territories, exceeding …
Entera Bio Ltd. (NASDAQ: ENTX) completed a private placement that generated aggregate proceeds of approximately $275.0 million. Ownership thresholds affect board nomination rights: if BVL’s beneficial ownership falls below 75%, its entitlement to nominate directors is reduced; a decline beneath 50% eliminates the right …
Iqvia's strong Q2 results have sent shockwaves through the healthcare sector, with the company's revenue climbing 8.7% to $4.368 billion and adjusted earnings increasing 12% to $3.15 per share. This solid performance has exceeded analyst expectations, with revenue beating the estimated $4.310 billion and …
NeoGenomics, Inc. reported a revenue increase of 11% year-over-year to $202 million for the second quarter of 2026, surpassing estimates. This growth reflects strong demand for advanced oncology testing, positioning the company for further expansion and profitability in the year ahead.Key HighlightsNeoGenomics posted $202 …
Repligen Corporation (NASDAQ: RGEN) has announced its financial results for the quarter ending June 30, 2026, revealing an earnings per share (EPS) of $0.54. This figure surpasses analysts' consensus estimate of $0.46, providing a positive signal to investors about its operational performance. The results …
Universal Health Services, Inc. (NYSE: UHS) delivered a second-quarter net income of $358.4 million, translating to $5.98 per diluted share. This fell slightly short of the $6.02 consensus estimate, reflecting challenges within the healthcare sector as it adapts to changing Medicaid conditions.
Altimmune (NASDAQ: ALT) achieved significant success with positive topline results from its Phase 2 trial of Pemvidutide for alcohol use disorder, leading to a market capitalization of approximately $576 million. This success may shape investor sentiment as the company aims for FDA meetings and …
Please wait processing your request...